Cargando…

Use of Minimal Residual Disease Status to Reduce Uncertainty in Estimating Long-term Survival Outcomes for Newly Diagnosed Multiple Myeloma Patients

Background: Demonstrating the cost-effectiveness of new treatments for multiple myeloma (MM) often relies on the extrapolation of overall survival (OS) trial data. This method can introduce uncertainty in long-term survival estimates if OS data are immature, as is often the case in newly diagnosed M...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Hest, Naomi, Morten, Peter, Stubbs, Keith, Trevor, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Columbia Data Analytics, LLC 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826714/ https://www.ncbi.nlm.nih.gov/pubmed/36688213 http://dx.doi.org/10.36469/001c.56072

Ejemplares similares

Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma
por: Daniele, Patrick, et al.
Publicado: (2022)

Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2023)

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
por: San-Miguel, Jesus, et al.
Publicado: (2022)

The prognostic significance of circulating plasma cells in newly diagnosed multiple myeloma patients
por: Yao, Weiqin, et al.
Publicado: (2023)

Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma
por: Yao, Qiumei, et al.
Publicado: (2019)

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2020)

Development and Validation of a Novel Prognostic Model for Overall Survival in Newly Diagnosed Multiple Myeloma Integrating Tumor Burden and Comorbidities
por: Jia, Shuangshuang, et al.
Publicado: (2022)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
por: Offidani, Massimo, et al.
Publicado: (2021)

Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches
por: Kostopoulos, Ioannis V., et al.
Publicado: (2020)

The (Neutrophils + Monocyte)/Lymphocyte Ratio Is an Independent Prognostic Factor for Progression-Free Survival in Newly Diagnosed Multiple Myeloma Patients Treated With BCD Regimen
por: Pang, Yanbin, et al.
Publicado: (2020)

Renal insufficiency predicts worse prognosis in newly diagnosed IgD multiple myeloma patients
por: Yan, Ge, et al.
Publicado: (2022)

“Friends and foes” of multiple myeloma measurable/minimal residual disease evaluation by next generation flow
por: Pacelli, Paola, et al.
Publicado: (2022)

High serum IL-17A is associated with bone destruction in newly diagnosed multiple myeloma patients
por: Dong, Mengmeng, et al.
Publicado: (2022)

CD20 expression: A risk stratification factor for newly diagnosed multiple myeloma with t(11;14)
por: Jian, Yuan, et al.
Publicado: (2022)

The independent adverse prognostic significance of 1q21 gain/amplification in newly diagnosed multiple myeloma patients
por: You, Hongying, et al.
Publicado: (2022)

Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy
por: Ferla, Valeria, et al.
Publicado: (2022)

Circulating Plasma Cells as a Biomarker to Predict Newly Diagnosed Multiple Myeloma Prognosis: Developing Nomogram Prognostic Models
por: Cheng, Qianwen, et al.
Publicado: (2021)

Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma
por: He, JingSong, et al.
Publicado: (2021)

Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting
por: Bonello, Francesca, et al.
Publicado: (2022)

Prediction of cardiovascular adverse events in newly diagnosed multiple myeloma: Development and validation of a risk score prognostic model
por: Yuan, Shuai, et al.
Publicado: (2023)

Acquired platelet dysfunction in newly diagnosed myeloma
por: Mortimer, Joshua, et al.
Publicado: (2021)

Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma: A Comparison With Real-Time Quantitative PCR
por: Yao, Qiumei, et al.
Publicado: (2021)

Decision-making factors for an autologous stem cell transplant for older adults with newly diagnosed multiple myeloma: A qualitative analysis
por: Mian, Owais, et al.
Publicado: (2023)

Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives
por: Romano, Alessandra, et al.
Publicado: (2019)

Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
por: Zhang, Yue, et al.
Publicado: (2019)

Minimal residual disease in multiple myeloma: current status
por: Ding, Hong, et al.
Publicado: (2021)

Therapy of newly diagnosed follicular lymphoma
por: Westin, Jason R., et al.
Publicado: (2012)

A Review of Newly Diagnosed Glioblastoma
por: Oronsky, Bryan, et al.
Publicado: (2021)

Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens
por: Liu, Xiao, et al.
Publicado: (2022)

Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population
por: Sørrig, Rasmus, et al.
Publicado: (2017)

Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety
por: Zhai, Yujia, et al.
Publicado: (2021)

HLC Pair Suppression as a Risk Factor for Bacterial Bloodstream Infections and Early Mortality in Newly Diagnosed Intact Immunoglobulin Multiple Myeloma Patients
por: Garcia de Veas Silva, Jose Luis, et al.
Publicado: (2021)

Hypertriglyceridemia in Newly Diagnosed Acute Promyelocytic Leukemia
por: Sun, Jianai, et al.
Publicado: (2020)

Dynamics of Minimal Residual Disease in Neuroblastoma Patients
por: Uemura, Suguru, et al.
Publicado: (2019)

Extreme body mass index and survival in newly diagnosed multiple myeloma patients
por: Shah, Urvi A., et al.
Publicado: (2023)

Body Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
por: Wang, Bei, et al.
Publicado: (2022)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
por: Rosiñol, Laura, et al.
Publicado: (2023)

The role of the bone microenvironment in regulating myeloma residual disease and treatment
por: Dadzie, Terry G., et al.
Publicado: (2022)

Indicators of distress in newly diagnosed breast cancer patients
por: Chirico, Andrea, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_961ddt2p4jufd1for736eijgs8